Meeting
2024 ASCO Annual Meeting
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).
Authors
Richard S. Finn
University of California, Los Angeles, Los Angeles, CA
Richard S. Finn , Makoto Ueno , Changhoon Yoo , Zhenggang Ren , Junji Furuse , Robin Kate Kelley , Stephen Lam Chan , Julien Edeline , Heinz-Josef Klümpen , Thomas Yau , Chris Verslype , Masato Ozaka , Mohamed Bouattour , Joon Oh Park , Arndt Vogel , Juan W. Valle , Liis Starkopf , Usha Malhotra , Abby B. Siegel , Shukui Qin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04003636
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4093)
DOI
10.1200/JCO.2024.42.16_suppl.4093
Abstract #
4093
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
First Author: Shubham Pant
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
First Author: Hendrik-Tobias Arkenau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang